Trials / Unknown
UnknownNCT05830513
OPU-LUX: Virtual Reality for Pain and Anxiety Management During Oocyte Pick-up
OPU-LUX: Virtual Reality for Pain and Anxiety Management During Oocyte Pick-up - a Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Luzerner Kantonsspital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 43 Years
- Healthy volunteers
- Accepted
Summary
In vitro fertilization (IVF) cycles are increasingly performed worldwide. Transvaginal oocyte pick-up (OPU) is a painful part of IVF. OPU in polyfollicular IVF is usually performed under sedation and pain relief. In natural cycle IVF or IVF with minimal stimulation OPU is possible without anesthesia. Mostly of the women reported experiencing mild to moderate pain when undergoing OPU without anesthesia. Nevertheless, there is a need for alternative pain treatment options during OPU to reduce the burden of IVF for patients. Virtual reality (VR) may have a role in acutely painful procedures as a non-pharmacological alternative. VR refers to the interactions between an individual and a computer-generated environment stimulating multiple sensory modalities. The immersive, entertaining effects of VR could be useful for redirecting the patient's attention away from painful treatment experiences and reducing anxiety, discomfort, or unpleasantness. Use of VR interventions has been studies in a wider range of medical treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Virtual Reality | Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects. |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2023-05-01
- Completion
- 2025-05-01
- First posted
- 2023-04-26
- Last updated
- 2023-04-26
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05830513. Inclusion in this directory is not an endorsement.